Related Experiment Video

Updated: Oct 25, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.5K

Cyclin-dependent kinase (CDK) inhibitors in solid tumors: a review of clinical trials

E Panagiotou1, G Gomatou2, I P Trontzas2

  • 1Oncology Unit, Sotiria General Hospital, Athens School of Medicine, 152 Mesogeion Avenue, 11527, Athens, Greece. em_panagiotou@outlook.com.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|August 7, 2021
PubMed

Insights

Cyclin-dependent kinase (CDK) inhibitors are revolutionizing cancer treatment. Newer, selective CDK inhibitors show promise in solid tumors, offering new therapeutic options and improved outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclin-dependent kinases (CDKs) are crucial regulators of the cell cycle, and their dysregulation is a hallmark of cancer, driving uncontrolled cell proliferation.
  • Early pan-CDK inhibitors faced challenges in clinical trials for solid tumors due to significant toxicity stemming from a lack of selectivity.
  • The development of selective CDK inhibitors, particularly CDK4/6 inhibitors, has transformed the treatment of hormone-receptor-positive metastatic breast cancer.

Purpose of the Study:

  • To review clinical trial data of CDK inhibitors in solid tumors.
  • To highlight novel CDK inhibitors and their therapeutic potential.
  • To explore potential new indications for CDK inhibitor-based therapies.

Main Methods:

  • Review of clinical trial data for CDK inhibitors in solid tumors.
  • Analysis of monotherapy and combination treatment regimens.
  • Focus on novel agents and emerging therapeutic strategies.

Main Results:

  • Selective CDK inhibitors, such as CDK4/6 inhibitors, have shown significant efficacy, particularly in HR+ metastatic breast cancer.
  • Trilaciclib has demonstrated benefits in mitigating chemotherapy-induced hematological toxicity in small cell lung cancer.
  • Newer agents like the selective CDK7 inhibitor SY-5609 show promising early clinical trial results.

Conclusions:

  • Selective CDK inhibitors represent a significant advancement in cancer therapy.
  • Ongoing research and development of novel CDK inhibitors are expanding treatment options for various solid tumors.
  • CDK inhibitors hold promise for new indications and improved patient outcomes in oncology.
Keywords:
Antineoplastic agentsCell cycle checkpointsClinical trialsCyclin-dependent kinasesProtein kinase inhibitors

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

18.9K
Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.2K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.8K
Positive Regulator Molecules02:39

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
8.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K